Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RXRX Recursion Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: RXRX
Price (delayed)
$4.25
Market cap
$1.73B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.81
Enterprise value
$1.32B
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients
Highlights
RXRX's revenue is up by 29% year-on-year
RXRX's equity has soared by 133% year-on-year but it is down by 10% since the previous quarter
The debt has surged by 82% year-on-year but it has declined by 14% since the previous quarter
The gross margin has dropped by 72% since the previous quarter and by 39% year-on-year
Recursion Pharmaceuticals's gross profit has plunged by 71% from the previous quarter and by 21% YoY
Key stats
What are the main financial stats of RXRX
Market
Valuations
Earnings
Shares outstanding
406.5M
Market cap
$1.73B
Enterprise value
$1.32B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.83
Price to sales (P/S)
28.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.03
Revenue
$59.79M
Gross profit
$3.89M
Operating income
-$574.03M
Net income
-$574.78M
EBIT
-$575.28M
EBITDA
-$506.56M
Free cash flow
-$397.71M
Per share
Balance sheet
Liquidity
EPS
-$1.81
EPS diluted
-$1.81
Free cash flow per share
-$0.99
Book value per share
$2.32
Revenue per share
$0.15
TBVPS
$2.01
Total assets
$1.31B
Total liabilities
$371.29M
Debt
$92.91M
Equity
$933.95M
Working capital
$442.16M
Debt to equity
0.1
Current ratio
4.11
Quick ratio
3.87
Net debt/EBITDA
0.81
Margins
Efficiency
Dividend
EBITDA margin
-847.2%
Gross margin
6.5%
Net margin
-961.3%
Operating margin
-960.1%
Return on assets
-54%
Return on equity
-74.7%
Return on invested capital
-241.6%
Return on capital employed
-49.5%
Return on sales
-962.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RXRX stock price
How has the Recursion Pharmaceuticals stock price performed over time
Intraday
-1.39%
1 week
-3.19%
1 month
-24.65%
1 year
-57.54%
YTD
-37.13%
QTD
-19.66%
Financial performance
How have Recursion Pharmaceuticals's revenue and profit performed over time
Revenue
$59.79M
Gross profit
$3.89M
Operating income
-$574.03M
Net income
-$574.78M
Gross margin
6.5%
Net margin
-961.3%
The gross margin has dropped by 72% since the previous quarter and by 39% year-on-year
Recursion Pharmaceuticals's gross profit has plunged by 71% from the previous quarter and by 21% YoY
Recursion Pharmaceuticals's net income has plunged by 62% YoY and by 24% from the previous quarter
Recursion Pharmaceuticals's operating income has shrunk by 52% YoY and by 20% QoQ
Price vs fundamentals
How does RXRX's price correlate with its fundamentals
Growth
What is Recursion Pharmaceuticals's growth rate over time
Valuation
What is Recursion Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.83
P/S
28.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
22.03
The company's EPS fell by 12% YoY and by 7% QoQ
RXRX's equity has soared by 133% year-on-year but it is down by 10% since the previous quarter
RXRX's price to book (P/B) is 55% lower than its 5-year quarterly average of 4.1 and 32% lower than its last 4 quarters average of 2.7
RXRX's price to sales (P/S) is 74% lower than its 5-year quarterly average of 109.4 and 14% lower than its last 4 quarters average of 33.1
RXRX's revenue is up by 29% year-on-year
Efficiency
How efficient is Recursion Pharmaceuticals business performance
The company's return on sales fell by 24% YoY and by 22% QoQ
RXRX's ROIC is up by 20% YoY but it is down by 10% QoQ
Recursion Pharmaceuticals's return on equity has increased by 7% YoY but it has decreased by 2.5% QoQ
Recursion Pharmaceuticals's return on assets has increased by 4.4% YoY but it has decreased by 2.1% QoQ
Dividends
What is RXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RXRX.
Financial health
How did Recursion Pharmaceuticals financials performed over time
The total liabilities has soared by 137% YoY but it has contracted by 10% from the previous quarter
The total assets has surged by 134% year-on-year but it has declined by 10% since the previous quarter
The debt is 90% smaller than the equity
RXRX's equity has soared by 133% year-on-year but it is down by 10% since the previous quarter
The debt has surged by 82% year-on-year but it has declined by 14% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.